Henry Schein, Inc. Q3 2026 Earnings Call Summary
Henry Schein reported Q3 2026 US dental merchandise growth of 8.6%, driven by volume. The company targets $200M in operating income improvements by 2026, with $125M expected by year-end. Non-GAAP EPS guidance raised to $5.50–$5.56. Management expects double-digit EPS growth in 2027, supported by value creation initiatives and portfolio shifts. Q3 included a $0.19 per share tariff refund benefit and $22M in restructuring expenses. Emmanuel Capre will succeed Ronald South as CFO in November 2026.
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 EPS and 2027 earnings power using the stated $125 million run-rate exiting 2026 and the raised $5.50–$5.56 non-GAAP EPS guidance, while adjusting for tariff-benefit normalization and restructuring costs.
Market read
The combination of a guidance raise, quantified cost-savings run-rate, and explicit normalization caveats around tariff refunds provides actionable inputs for near-term positioning and 2027 expectation setting.
What to watch
Restructuring expenses ($22 million) and assumptions around an early 2027 flu season to offset point-of-care diagnostic demand declines could create earnings volatility if timing differs.
Background
The piece summarizes Henry Schein’s Q3 2026 earnings call, focusing on a “Value Creation” plan, guidance changes, segment demand dynamics, and organizational simplification.
Ticker impact
Henry Schein raised full-year 2026 non-GAAP EPS guidance to $5.50–$5.56 and outlined a $125 million 2026 savings run-rate plus CFO succession.
Likely upward bias as traders price in higher 2026 EPS and the 2027 earnings trajectory from the stated run-rate, tempered by normalization risk after the tariff refund.
The article provides specific EPS guidance, a quantified savings run-rate exiting 2026, and notes the $0.19 tariff refund is difficult to repeat, which should moderate enthusiasm.
Market effects
US dental distribution and specialty products demand signals (volume-driven growth, steady routine demand) may influence sentiment across dental supply and practice-management software peers.
Brazil election-related volatility is cited as a headwind for the global specialty products segment, which could affect regional risk premia for dental distributors.
Tariff refund accounting and procedural mix shifts (acute to alternate care and home solutions) reinforce broader healthcare supply-chain and care-delivery trend narratives.
Counterpoint
The raised EPS guidance includes a tariff refund benefit and management explicitly says it is difficult to repeat, so underlying momentum may be less durable than the headline implies.
Key entities
- companyHenry Schein, Inc.
Raised full-year 2026 non-GAAP EPS guidance to $5.50–$5.56, targeting $200 million operating income improvements and a $125 million run-rate exiting 2026.
- executiveEmmanuel Capre
Named successor CFO effective November 4, 2026, succeeding Ronald South.
